DNA Gyrase Subunit B (EC 5.99.1.3) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘DNA Gyrase Subunit B (EC 5.99.1.3)- Pipeline Review, H2 2019’, provides in depth analysis on DNA Gyrase Subunit B (EC 5.99.1.3) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Infectious Disease under development targeting DNA Gyrase Subunit B (EC 5.99.1.3).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for DNA Gyrase Subunit B (EC 5.99.1.3)

– The report reviews DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics and enlists all their major and minor projects

– The report assesses DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for DNA Gyrase Subunit B (EC 5.99.1.3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding DNA Gyrase Subunit B (EC 5.99.1.3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Abgentis Ltd

AstraZeneca Plc

Daiichi Sankyo Co Ltd

Spero Therapeutics Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

DNA Gyrase Subunit B (EC

5.99.1.3) Overview

DNA Gyrase Subunit B (EC

5.99.1.3) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

DNA Gyrase Subunit B (EC

5.99.1.3) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

DNA Gyrase Subunit B (EC

5.99.1.3) Companies Involved in Therapeutics Development

Daiichi Sankyo Co Ltd

Spero Therapeutics Inc

DNA Gyrase Subunit B (EC

5.99.1.3) Drug Profiles

DS-11960558 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-2969 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GYR-12 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPR-720 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-12008911 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXC-100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNA Gyrase Subunit B (EC

5.99.1.3) Dormant Products

DNA Gyrase Subunit B (EC

5.99.1.3) Product Development Milestones

Featured News & Press Releases

Jun 05, 2018: Spero Therapeutics to Present Data On SPR720 at ASM Microbe 2018

May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017

May 04, 2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Abgentis Ltd, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Pipeline by Spero Therapeutics Inc, H2 2019

Dormant Projects, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019”

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports